215 related articles for article (PubMed ID: 32430683)
1. Downregulation of beta-catenin in chemo-tolerant TNBC through changes in receptor and antagonist profiles of the WNT pathway: Clinical and prognostic implications.
Islam S; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Panda CK
Cell Oncol (Dordr); 2020 Aug; 43(4):725-741. PubMed ID: 32430683
[TBL] [Abstract][Full Text] [Related]
2. Reduction of nuclear Y654-p-β-catenin expression through SH3GL2-meditated downregulation of EGFR in chemotolerance TNBC: Clinical and prognostic importance.
Islam MS; Dasgupta H; Basu M; Roy A; Alam N; Roychoudhury S; Kumar Panda C
J Cell Physiol; 2020 Nov; 235(11):8114-8128. PubMed ID: 31960967
[TBL] [Abstract][Full Text] [Related]
3. Nek2B activates the wnt pathway and promotes triple-negative breast cancer chemothezrapy-resistance by stabilizing β-catenin.
Shen H; Yan W; Yuan J; Wang Z; Wang C
J Exp Clin Cancer Res; 2019 Jun; 38(1):243. PubMed ID: 31174562
[TBL] [Abstract][Full Text] [Related]
4. A novel recombinant human Frizzled-7 protein exhibits anti-tumor activity against triple negative breast cancer via abating Wnt/β-catenin pathway.
Xie W; Zhang Y; He Y; Zhang K; Wan G; Huang Y; Zhou Z; Huang G; Wang J
Int J Biochem Cell Biol; 2018 Oct; 103():45-55. PubMed ID: 30096373
[TBL] [Abstract][Full Text] [Related]
5. Niclosamide sensitizes triple-negative breast cancer cells to ionizing radiation in association with the inhibition of Wnt/β-catenin signaling.
Yin L; Gao Y; Zhang X; Wang J; Ding D; Zhang Y; Zhang J; Chen H
Oncotarget; 2016 Jul; 7(27):42126-42138. PubMed ID: 27363012
[TBL] [Abstract][Full Text] [Related]
6. Differential Wnt-β- catenin pathway activation in HPV positive and negative oral epithelium is transmitted during head and neck tumorigenesis: clinical implications.
Chakraborty B; Mukhopadhyay D; Roychowdhury A; Basu M; Alam N; Chatterjee K; Chakrabarti J; Panda CK
Med Microbiol Immunol; 2021 Feb; 210(1):49-63. PubMed ID: 33226516
[TBL] [Abstract][Full Text] [Related]
7. Destabilization of β-catenin and RAS by targeting the Wnt/β-catenin pathway as a potential treatment for triple-negative breast cancer.
Ryu WJ; Lee JD; Park JC; Cha PH; Cho YH; Kim JY; Sohn JH; Paik S; Choi KY
Exp Mol Med; 2020 May; 52(5):832-842. PubMed ID: 32457491
[TBL] [Abstract][Full Text] [Related]
8. Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner.
Dey N; Young B; Abramovitz M; Bouzyk M; Barwick B; De P; Leyland-Jones B
PLoS One; 2013; 8(10):e77425. PubMed ID: 24143235
[TBL] [Abstract][Full Text] [Related]
9. miR-221/222 activate the Wnt/β-catenin signaling to promote triple-negative breast cancer.
Liu S; Wang Z; Liu Z; Shi S; Zhang Z; Zhang J; Lin H
J Mol Cell Biol; 2018 Aug; 10(4):302-315. PubMed ID: 30053090
[TBL] [Abstract][Full Text] [Related]
10. Frequent inactivation of MCC/CTNNBIP1 and overexpression of phospho-beta-catenin(Y654) are associated with breast carcinoma: Clinical and prognostic significance.
Mukherjee N; Dasgupta H; Bhattacharya R; Pal D; Roy R; Islam S; Alam N; Biswas J; Roy A; Roychoudhury S; Panda CK
Biochim Biophys Acta; 2016 Sep; 1862(9):1472-84. PubMed ID: 27208794
[TBL] [Abstract][Full Text] [Related]
11. Increase in ADAR1p110 activates the canonical Wnt signaling pathway associated with aggressive phenotype in triple negative breast cancer cells.
Morales F; Pérez P; Tapia JC; Lobos-González L; Herranz JM; Guevara F; de Santiago PR; Palacios E; Andaur R; Sagredo EA; Marcelain K; Armisén R
Gene; 2022 Apr; 819():146246. PubMed ID: 35122924
[TBL] [Abstract][Full Text] [Related]
12. The pan-PI3K inhibitor GDC-0941 activates canonical WNT signaling to confer resistance in TNBC cells: resistance reversal with WNT inhibitor.
Tzeng HE; Yang L; Chen K; Wang Y; Liu YR; Pan SL; Gaur S; Hu S; Yen Y
Oncotarget; 2015 May; 6(13):11061-73. PubMed ID: 25857298
[TBL] [Abstract][Full Text] [Related]
13. CircRNA_069718 promotes cell proliferation and invasion in triple-negative breast cancer by activating Wnt/β-catenin pathway.
Zhang J; Xu HD; Xing XJ; Liang ZT; Xia ZH; Zhao Y
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5315-5322. PubMed ID: 31298383
[TBL] [Abstract][Full Text] [Related]
14. A novel humanized Frizzled-7-targeting antibody enhances antitumor effects of Bevacizumab against triple-negative breast cancer via blocking Wnt/β-catenin signaling pathway.
Xie W; Zhao H; Wang F; Wang Y; He Y; Wang T; Zhang K; Yang H; Zhou Z; Shi H; Wang J; Huang G
J Exp Clin Cancer Res; 2021 Jan; 40(1):30. PubMed ID: 33436039
[TBL] [Abstract][Full Text] [Related]
15. RAC1 GTP-ase signals Wnt-beta-catenin pathway mediated integrin-directed metastasis-associated tumor cell phenotypes in triple negative breast cancers.
De P; Carlson JH; Jepperson T; Willis S; Leyland-Jones B; Dey N
Oncotarget; 2017 Jan; 8(2):3072-3103. PubMed ID: 27902969
[TBL] [Abstract][Full Text] [Related]
16. Kinesin family member 23, regulated by FOXM1, promotes triple negative breast cancer progression via activating Wnt/β-catenin pathway.
Li Z; Yang HY; Zhang XL; Zhang X; Huang YZ; Dai XY; Shi L; Zhou GR; Wei JF; Ding Q
J Exp Clin Cancer Res; 2022 May; 41(1):168. PubMed ID: 35524313
[TBL] [Abstract][Full Text] [Related]
17. Interference KRT17 reverses doxorubicin resistance in triple-negative breast cancer cells by Wnt/β-catenin signaling pathway.
Wu L; Ding W; Wang X; Li X; Yang J
Genes Genomics; 2023 Oct; 45(10):1329-1338. PubMed ID: 37634232
[TBL] [Abstract][Full Text] [Related]
18. Dual targeting of Notch and Wnt/β-catenin pathways: Potential approach in triple-negative breast cancer treatment.
Nasser F; Moussa N; Helmy MW; Haroun M
Naunyn Schmiedebergs Arch Pharmacol; 2021 Mar; 394(3):481-490. PubMed ID: 33052427
[TBL] [Abstract][Full Text] [Related]
19. TOPK: A new predictor of the therapeutic response to neoadjuvant chemotherapy and prognosis in triple-negative breast cancer.
Wang K; Chai J; Xu J; Wei J; Li P; Liu Y; Ma J; Xu T; Zhao D; Yu K; Fan L; Yan Q; Guo S; Li M; Wang Z
Pathol Res Pract; 2021 Oct; 226():153603. PubMed ID: 34500374
[TBL] [Abstract][Full Text] [Related]
20. Coordinated regulation of WNT/β-catenin, c-Met, and integrin signalling pathways by miR-193b controls triple negative breast cancer metastatic traits.
Giacomelli C; Jung J; Wachter A; Ibing S; Will R; Uhlmann S; Mannsperger H; Sahin Ö; Yarden Y; Beißbarth T; Korf U; Körner C; Wiemann S
BMC Cancer; 2021 Dec; 21(1):1296. PubMed ID: 34863149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
